Keith Cengel, MD, PhD
Abramson Cancer Center at Penn Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Keith Cengel, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:31 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02698293 · PDT Plus Vitamin D3 for Anal DysplasiaAbramson Cancer Center at Penn Medicine · withdrawn · Anal Dysplasia, Carcinoma in Situ · principal investigator
- N/ANCT02469194 · Mechanisms and Predictors of Unusual Radiation or Chemotherapy ToxicityAbramson Cancer Center at Penn Medicine · withdrawn · Severe or Mild Toxicity From Radiotherapy and/or Chemotherapy · principal investigator
- Ph2NCT02153229 · Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural MesotheliomaAbramson Cancer Center at Penn Medicine · active not recruiting · Epitheliod Malignant Pleural Mesothelioma · principal investigator
- Ph2NCT00601848 · Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the PleuraAbramson Cancer Center at Penn Medicine · terminated · Lung Cancer, Metastatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:31 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.